An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria

Expert Review of Clinical Immunology

Volumn 8, Issue 1, 2012, Pages 33-41

  Jàuregui, Ignacio ^a   García Lirio, Eduardo ^a   Soriano, Ana Ma ^a   Gamboa, Pedro M ^a   Antépara, Ignacio ^a  

^a HOSPITAL DE BASURTO   (Spain)

Author keywords

allergic rhinitis; antihistamine; bilastine; histamine H1 receptor antagonist; urticaria

Indexed keywords

BILASTINE; CETIRIZINE; DESLORATADINE; HISTAMINE H1 RECEPTOR; KETOCONAZOLE; LEVOCETIRIZINE; MOXIFLOXACIN;

ALLERGIC RHINITIS; ARTICLE; CARDIOVASCULAR EFFECT; DRIVING ABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; NONHUMAN; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; URTICARIA;

AUTOMOBILE DRIVING; BENZIMIDAZOLES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HISTAMINE H1 ANTAGONISTS; HUMANS; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 83455211994     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.87     Document Type: Article

References (42)

1. Bousquet J, Burney PG, Zuberbier T et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma epidemic. Allergy 64, 969-977 (2009).
2. Léger D, Annesi-Maesano I, Carat F et al. Allergic rhinitis and its consequences on quality of sleep. An unexplored area. Arch. Intern. Med. 166, 1744-1748 (2006).
3. Jáuregui I, Mullol J, Dávila I et al. Allergic rhinitis and school performance. J. Investig. Allergol. Clin. Immunol. 19(Suppl. 1), S32-S39 (2009).
4. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 22, 345-361 (2004).
5. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 126, 466-476 (2010).
6. Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am. J. Manag. Care 5, 485-496 (1999).
7. Zuberbier T, Maurer M. Urticaria: Current opinions about etiology, diagnosis and therapy. Acta Derm. Venereol. 87, 196-205 (2007).
8. Ferrer M, Kaplan AP. Progress and challenges in the understanding of chronic urticaria. Allergy Asthma Clin. Immunol. 3, 31-35 (2007).
9. Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br. J. Dermatol. 160, 633-641 (2009).
10. Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin. Exp. Allergy 29(Suppl. 3), S1-S11 (1999).
11. Nicholson AN. Central effects of H1 and H2 antihistamines. Aviat. Space Environ. Med. 56, 293-298 (1985).
12. Simons FE. Advances in H1-antihistamines. N. Engl. J. Med. 351, 2203-2217 (2004).
13. Church MK, Maurer M, Simons FER et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 65, 459-466 (2010).
14. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 64, 1427-1443 (2009).
15. Ferrer M, Sastre J, Jáuregui I et al. Effect of antihistamine dose escalation in chronic urticaria. J. Investig. Allergol. Clin. Immunol. 21(Suppl. 3), S34-S39 (2011).
16. Woosley RL. Cardiac actions of antihistamines. Ann. Rev. Pharmacol. Toxicol. 36, 233-252 (1996).
17. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN Task Force report. Allergy 66, 317-330 (2011).
18. Marple BF, Fornadley JA, Patel AA et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol. Head Neck Surg. 136(Suppl. 6), S107-S124 (2007).
19. Ferrer E, Pandian R, Bolós J, Castañer R. Bilastine. Drugs Future 35(2), 98-105 (2010).
20. Holgate ST, Canonica GW, Simons FER et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin. Exp. Allergy 33, 1305-1324 (2003).
21. Corcóstegui R, Labeaga L, Innerarity A et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs RD 6(6), 371-384 (2005).
22. Corcóstegui R, Labeaga L, Innerárity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs RD 7(4), 219-231 (2006).
23. Alvarez-Mon M, San Antonio E, Lucero M et al. Bilastine, a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 64(Suppl. 90), 555 (2009).
24. Sologuren A, Valiente R, Crean C, McLaverty D. Relationship of dose to inhibiton of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. Presented at: American College of Clinical Pharmacology (ACCP) 36th Annual Meeting. San Francisco, CA, USA, 9-11 September 2007 (Abstract 69).
25. Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodriguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin. Pharmacokinet. 48(8), 543-554 (2009).
26. Sologuren A, Lucero ML, Valiente R et al. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Basic Clin. Pharmacol. Toxicol. 105(Suppl. 1), Abstract TP85 (2009).
27. Crean C, Valiente R, Sologuren A, McLaverty D. Effect of grapefruit juice on the pharmacokinetics of bilastine. J. Clin. Pharmacol. 47(9), 71 (2007).
28. Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br. J. Clin. Pharmacol. 70, 645-655 (2010).
29. Crean C, Sologuren A, Valiente R, McLaverty D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin. Pharmacol. Toxicol. 101(Suppl. 1), Abstract P253 (2007).
30. Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 65(Suppl. 93), S1-S13 (2010).
31. Garcia-Gea C, Clos S, Antonioli DA et al. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinial trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg ) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin. Pharmacol. Toxicol. 99(Suppl. 1), 30 (2006).
32. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp. Opin. Drug Saf. 10(5), 779-793 (2011).
33. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna challenge chamber. Inflamm. Res. 59, 391-398 (2010).
34. Bachert C, Kuna P, Sanquer F et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 64, 158-165 (2009).
35. Kuna P, Bachert C, Nowacki Z et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin. Exp. Allergy 39, 1338-1347 (2009).
36. Zuberbier T, Oanta A, Bogacka E et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 65(4), 516-528 (2010).
37. Taglialatela M, Pannaccione A, Castaldo P et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol. 54, 113-121 (1998).
38. Tyl B, Kabbaj M, Azzam S et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J. Clin. Pharmacol. doi:10.1177/ 0091270011407191 (2011) (Epub ahead of print).
39. Montoro J, Sastre J, Bartra J et al. Effect of H1 antihistamines upon the central nervous system. J. Investig. Allergol. Clin. Immunol. 16(Suppl. 1), S24-S28 (2006).
40. Montoro J, Mullol J, Dávila IJ et al. Bilastine and the central nervous system. J. Investig. Allergol. Clin. Immunol. 21(Suppl. 3), S9-S15 (2011).
41. García-Gea C, Martínez-Colomer J, Antonijoan RM et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J. Clin. Psychopharmacol. 28(6), 675-685 (2008).
42. Conen S, Theunissen EL, Van Oers et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J. Psychopharmacol. doi:10.1177/0269881110382467 (2010) (Epub ahead of print).